A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Summary

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

Timeline

Start

2012-05

Primary completion

2012-09

Completion

2013-03

Outcome

Met primary endpoint

registry analysis (superiority test); 122-0551 vs Vehicle; p <0.0001; Fisher Exact NCT01700985 ↗

Drugs

Indications